Adaptive Biotechnologies Corp
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
ADPT$29.36-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Operating activities | |||
| Net loss | $(225,304) | $(200,368) | $(207,298) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Depreciation expense | 20,532 | 19,221 | 12,254 |
| Noncash lease expense | 6,920 | 7,227 | 7,028 |
| Share-based compensation expense | 62,908 | 55,477 | 43,251 |
| Intangible assets amortization | 1,699 | 1,699 | 1,699 |
| Investment amortization | (9,184) | 741 | 7,233 |
| Impairment of right-of-use and related long-lived assets | 25,429 | — | — |
| Inventory reserve | 1,387 | 2,638 | — |
| Noncash interest expense | 5,300 | 985 | — |
| Other | 172 | (19) | (78) |
| Changes in operating assets and liabilities | |||
| Accounts receivable, net | 2,032 | (22,648) | (7,362) |
| Inventory | (2,838) | 817 | (5,200) |
| Prepaid expenses and other current assets | (1,930) | 3,551 | 1,286 |
| Accounts payable and accrued liabilities | (5,407) | 7,111 | 3,940 |
| Operating lease right-of-use assets and liabilities | (8,676) | (4,050) | 8,522 |
| Deferred revenue | (29,291) | (56,496) | (57,727) |
| Other | (73) | 169 | (275) |
| Net cash used in operating activities | (156,324) | (183,945) | (192,727) |
| Investing activities | |||
| Purchases of property and equipment | (10,697) | (16,349) | (61,746) |
| Purchases of marketable securities | (429,558) | (278,778) | (316,544) |
| Proceeds from maturities of marketable securities | 569,902 | 298,032 | 559,500 |
| Net cash provided by investing activities | 129,647 | 2,905 | 181,210 |
| Financing activities | |||
| Proceeds from exercise of stock options | 2,245 | 7,890 | 26,717 |
| Proceeds from revenue interest purchase agreement, net of issuance costs | — | 124,375 | — |
| Proceeds from initial capital contributions for Digital Biotechnologies, Inc. | — | — | 429 |
| Net cash provided by financing activities | 2,245 | 132,265 | 27,146 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (24,432) | (48,775) | 15,629 |
| Cash, cash equivalents and restricted cash at beginning of year | 92,428 | 141,203 | 125,574 |
| Cash, cash equivalents and restricted cash at end of year | $67,996 | $92,428 | $141,203 |
| Noncash investing activities | |||
| Purchases of equipment included in accounts payable and accrued liabilities | $687 | $1,719 | $682 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | $8,985 | $494 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.